Amgen Receives NMPA Approval For Repatha In China To Reduce The Risk Of Cardiovascular Events
Amgen announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha as the first PCSK9...
Amgen announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha as the first PCSK9...
Sanofi has received approval from the US FDA for 0.5ml Fluzone Quadrivalent vaccine to treat influenza in children aged between...
PeptiDream has signed a deal with fellow Japanese pharmaceutical company Shionogi to discover and develop a series of blood-brain barrier...
TC BioPharm (TCB), a developer of CAR-T immuno-oncology products, including Gamma Delta T (GDT) cell therapies, announced it has completed...
Astellas Pharma Inc and KM Biologics Co., Ltd. announced that the agreement for the distribution by Astellas of human vaccines,...
TrakCel, a UK-based developer of cell and gene therapy supply-chain tracking and orchestration systems software, and The Quick Life Science...
Novartis has partnered with the University of Oxford’s Big Data Institute (BDI) to boost drug development using artificial intelligence (AI)...
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on novel, disease-modifying therapies for neurodegenerative diseases announced its plans to initiate...
The Almac Group is expanding its Edinburgh Technopole facility to allow scale-up of its personalized cancer vaccine activities. Doubling its...
As China continues to advance from a big country in pharmaceuticals to a power in pharmaceuticals, and the global economy...
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
© 2017 Copyright © Valuemediaservices 2017 All rights reserved.